Imagen de Portada

Dose Individualization for Phase I Cancer Trials With Broadened Eligibility

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Rebecca B. Silva, Bin Cheng, Richard D. Carvajal, Shing M. Lee
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Statistics in Medicine
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Accounting for Carryover Toxicity in Phase I Clinical Trials with Intra‐Patient Dose Escalation
por: Chloe E. Falke, et al.
Publicado: (2025)

Defining Utility as a Measure of Preference Under Uncertainty in Phase I– II Oncology Dose Finding Trials
por: Andrew Hall, et al.
Publicado: (2026)

A Generalized Phase I/II Dose Optimization Trial Design With Multi‐Categorical and Multi‐Graded Outcomes
por: Yichen Yan, et al.
Publicado: (2025)

Testing for Similarity of Dose Response in Multiregional Clinical Trials
por: Holger Dette, et al.
Publicado: (2025)

Bayesian Ordered Lattice Design for Phase I Clinical Trials
por: Gi‐Ming Wang, et al.
Publicado: (2026)

A Bayesian Treatment Selection Design for Phase II Randomised Cancer Clinical Trials
por: Moka Komaki, et al.
Publicado: (2026)

On Inclusion of Covariates in Model Based Dose Finding Clinical Trial Designs
por: Adrien Ollier, et al.
Publicado: (2025)

A Biomarker‐Based Dose–Schedule Optimization Design for Immunotherapy Trials
por: Yingjie Qiu, et al.
Publicado: (2026)

Sample Size Calculation in Dose Optimization Trials Using the Margin of Practical Non‐Inferiority
por: Hakim‐Moulay Dehbi, et al.
Publicado: (2025)

Bayesian Safety and Futility Monitoring in Phase II Trials Using One Utility‐Based Rule
por: Juhee Lee, et al.
Publicado: (2024)

Handling Missing Outcome Data in Cluster Randomized Trials With Both Individual‐ and Cluster‐Level Dropout
por: Analissa Avila, et al.
Publicado: (2025)

BAR12 : Bayesian Autoregressive Phase 1‐2 Design for Cell Therapy Trials With Manufacturing Changes
por: Cheng‐Han Yang, et al.
Publicado: (2026)

Towards Efficient Time‐to‐Event Dose‐Escalation Guidance of Multi‐Cycle Cancer Therapies
por: Lukas A. Widmer, et al.
Publicado: (2025)

Design and Analysis of N‐Of‐1 Trials That Incorporate Sequential Monitoring
por: Shu Jiang, et al.
Publicado: (2025)

Doubly Robust Estimators of the Restricted Mean Time in Favor Estimands in Individual‐ and Cluster‐Randomized Trials
por: Xi Fang, et al.
Publicado: (2026)

Adaptive Biomarker‐Based Design for Early Phase Clinical Trials
por: Alessandra Serra, et al.
Publicado: (2025)

The Design of Large‐Scale Plasma Donation Trials
por: Kecheng Li, et al.
Publicado: (2025)

DOD ‐ SSR : An Adaptive Seamless Phase II / III Design With Dose Optimization Decision and Sample Size Re‐estimation
por: Meizi Liu, et al.
Publicado: (2025)

Exact Randomized Two‐Stage Phase 2 Clinical Trial Designs for Two Binary Co‐Primary Endpoints
por: Hyejung Jung, et al.
Publicado: (2026)

Preference‐Informed Cluster Randomized Design for Pragmatic Clinical Trials
por: Yuwei Cheng, et al.
Publicado: (2026)

Cluster‐Level Analyses to Estimate a Risk Difference in a Cluster Randomized Trial With Confounding Individual‐Level Covariates: A Simulation Study
por: Jules Antoine Pereira Macedo, et al.
Publicado: (2025)

Model‐Robust Standardization in Cluster‐Randomized Trials
por: Fan Li, et al.
Publicado: (2025)

Cumulative Logit Ordinal Regression With Proportional Odds Under Nonignorable Missing Responses—Application to Phase III Trial
por: Arnab Kumar Maity, et al.
Publicado: (2025)

Using Propensity Score Weighting With Clustered Data When the Treatment Is Applied at the Level of the Cluster and Outcomes Are Assessed at the Level of the Individual: The Observational Analog of Cluster Randomization Trials
por: Peter C. Austin
Publicado: (2026)

Futility Monitoring in Clinical Trials
por: Ana M. Ortega‐Villa, et al.
Publicado: (2025)

The Win Ratio Approach in Bayesian Monitoring for Two‐Arm Phase II Clinical Trial Designs With Multiple Time‐To‐Event Endpoints
por: Xinran Huang, et al.
Publicado: (2024)

Negative Control Outcome Adjustment in Early‐Phase Randomized Trials: Estimating Vaccine Effects on Immune Responses in HIV Exposed Uninfected Infants
por: Ethan Ashby, et al.
Publicado: (2025)

Estimating Risk Factors for Pathogenic Dose Accrual From Longitudinal Data
por: Daniel K. Sewell, et al.
Publicado: (2025)

Doubly Robust Estimation and Sensitivity Analysis With Outcomes Truncated by Death in Multi‐Arm Clinical Trials
por: Jiaqi Tong, et al.
Publicado: (2025)

Active‐Controlled Trial Design for HIV Prevention Trials With a Counterfactual Placebo
por: Fei Gao, et al.
Publicado: (2025)

On Anticipation Effect in Stepped Wedge Cluster Randomized Trials
por: Hao Wang, et al.
Publicado: (2026)

Dual‐agent dose‐finding in Phase I clinical trial—An extension of rapid enrollment design
por: Yunfei Wang
Publicado: (2024)

Clinical Trial Simulation: Planning With the OCTAVE Framework, Implementation and Validation Principles
por: Kim May Lee, et al.
Publicado: (2026)

Modern Causal Inference Approaches to Improve Power for Subgroup Analysis in Randomized Controlled Trials
por: Antonio D'Alessandro, et al.
Publicado: (2026)

COMIC: A Bayesian Dose Optimization Design for Drug Combination in Multiple Indications With Application to CAR‐T Therapies
por: Kai Chen, et al.
Publicado: (2025)

A Bayesian Location‐Scale Joint Model for Time‐To‐Event and Multivariate Longitudinal Data With Association Based on Within‐Individual Variability
por: Marco Palma, et al.
Publicado: (2026)

Estimation and Hypothesis Testing of Strain‐Specific Vaccine Efficacy With Missing Strain Types With Application to a COVID‐19 Vaccine Trial
por: Fei Heng, et al.
Publicado: (2025)

Individualized empirical null estimation for exact tests of healthcare quality
por: Nicholas Hartman, et al.
Publicado: (2024)

Reinforced Borrowing Framework: Leveraging Auxiliary Data for Individualized Inference
por: Ziyu Ji, et al.
Publicado: (2024)

Using Individualized Treatment Effects to Assess Treatment Effect Heterogeneity
por: Konstantinos Sechidis, et al.
Publicado: (2025)